HC Wainwright Cuts Carisma Therapeutics (NASDAQ:CARM) Price Target to $5.00

Carisma Therapeutics (NASDAQ:CARM) had its target price trimmed by HC Wainwright from $8.00 to $5.00 in a research report report published on Monday morning,Benzinga reports. The firm currently has a buy rating on the stock. HC Wainwright also issued estimates for Carisma Therapeutics’ FY2024 earnings at ($1.32) EPS, Q1 2025 earnings at ($0.28) EPS, Q2 2025 earnings at ($0.27) EPS, Q3 2025 earnings at ($0.22) EPS and FY2025 earnings at ($1.00) EPS.

Separately, EF Hutton Acquisition Co. I raised Carisma Therapeutics to a “strong-buy” rating in a report on Wednesday, October 30th.

Carisma Therapeutics Stock Performance

Shares of CARM stock opened at $0.84 on Monday. The company has a current ratio of 3.23, a quick ratio of 3.23 and a debt-to-equity ratio of 1.39. The business’s 50 day moving average is $0.96 and its two-hundred day moving average is $1.09. The company has a market capitalization of $35.11 million, a P/E ratio of -0.54 and a beta of 1.49. Carisma Therapeutics has a 12-month low of $0.80 and a 12-month high of $3.16.

Carisma Therapeutics (NASDAQ:CARM) last issued its earnings results on Thursday, November 7th. The company reported ($0.31) EPS for the quarter, meeting analysts’ consensus estimates of ($0.31). Carisma Therapeutics had a negative net margin of 314.78% and a negative return on equity of 957.20%. The business had revenue of $3.39 million during the quarter. Analysts expect that Carisma Therapeutics will post -1.33 EPS for the current fiscal year.

Institutional Trading of Carisma Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in CARM. Wexford Capital LP grew its position in Carisma Therapeutics by 75.5% in the third quarter. Wexford Capital LP now owns 34,861 shares of the company’s stock worth $34,000 after acquiring an additional 15,000 shares during the period. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Carisma Therapeutics in the 2nd quarter valued at $40,000. Barclays PLC grew its holdings in shares of Carisma Therapeutics by 3,661,933.3% during the 3rd quarter. Barclays PLC now owns 549,305 shares of the company’s stock worth $539,000 after purchasing an additional 549,290 shares during the period. Finally, Vanguard Group Inc. increased its position in shares of Carisma Therapeutics by 0.7% during the 1st quarter. Vanguard Group Inc. now owns 1,579,961 shares of the company’s stock worth $3,587,000 after purchasing an additional 11,200 shares during the last quarter. Institutional investors and hedge funds own 44.27% of the company’s stock.

About Carisma Therapeutics

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.